GSK's phase 3 trial shows Blenrep combined with BorDex improves overall survival in relapsed multiple myeloma.

Equecabtagene autoleucel produced “remarkable” responses in patients whose disease progressed after prior BCMA CAR T-cell therapy, researchers reported.

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...

GSK reported positive survival data for Blenrep combined with bortezomib and dexamethasone in multiple myeloma DREAMM-7 trial, outperforming daratumumab combination therapy. GSK plans US relaunch in ...

(Alliance News) - GSK PLC on Thursday said its Blenrep drug has shown overall survival benefits in patients with relapsed or refractory multiple myeloma, the third most common type of blood cancer.

Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...